News & Events


RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing

SEATTLE, Dec. 19, 2019 - RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors. The funding will drive a global sales expansion for its instrument and consumables platform used in research and clinical markets. The $22M investment was led by HealthQuest Capital, with participation from 5AM Ventures and company founder, Ron Seubert.


RareCyte expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit

SEATTLE, Oct. 31, 2019 /PRNewswire/ -- RareCyte announces an addition to the RarePlex® Staining Kit product line, enabling customers to evaluate HER2 and ER expression on circulating tumor cells (CTCs) in their own laboratory. HER2 and ER are biomarkers that direct treatment recommendations for invasive breast cancer, and liquid biopsy offers a blood-based method to evaluate biomarker expression for insight into receptor status, response to treatment, and potentially therapy selection in clinical research.


RareCyte launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis

SEATTLE, Oct. 30, 2019 - RareCyte announces the launch of a new RarePlex® Staining Kit, enabling customers to evaluate prostate cancer specific expression of ARv7 on circulating tumor cells (CTC) in their own laboratory. ARv7 is the result of a splice variant of Androgen Receptor (AR), a diagnostic prostate cancer biomarker, and ARv7 is associated with resistance to second generation therapies. Liquid biopsy offers a blood-based method for researchers to evaluate CTC biomarker expression and gain insight into tumor status without an invasive biopsy.


New RarePlex® Developer Kits for CTC characterization provide researchers flexibility in independent CTC assay development

SEATTLE, Oct. 29, 2019 - RareCyte® announces the launch of the of RarePlex® Developer Kits that uniquely enable customers to add their own biomarkers to RareCyte circulating tumor cell (CTC) assays in their own lab. Kyla Teplitz, Sr. Product Manager said, "The understanding of cancer heterogeneity and evolution is a rapidly evolving field, and it is important that our customers have the tools that allow them to keep pace. We are excited to launch our Developer platform to enable our customers to create their own CTC assays while leveraging RareCyte's robust liquid biopsy platform."


RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in Atlanta

Seattle, WA, March 28, 2019 – RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in Atlanta, March 29 through April 3. These next generation CyteFinder Instruments expand on RareCyte’s world class liquid biopsy platform to support tissue workflows. Both instruments perform rapid, whole slide imaging in seven fluorescence channels as well as brightfield for IF, IHC, and H&E samples and are designed for placement in clinical laboratories. Together, the CyteFinder II systems provide one platform for fast, multiplexed imaging with multi-omic results.



Liquid Biopsy Summit 2020

20-21 February 2020
Myriad by SANA
Lisbon, Portual

Molecular Med Tri-Con 2020

1-4 March 2020
Moscone South Convention Center
San Francisco, CA

AACR 2020

24-29 April 2020
San Diego Convention Center
San Diego, CA

ASCO 2020

29 May - 2 June 2020
McCormick Center
Chicago, IL